Table 2.
Antiproliferative Activity of the Selected Acetophenone Monomers
| compound | cell linesa (IC50μM)b
|
||||
|---|---|---|---|---|---|
| A549 | KB | KB-VIN | MDA-MB-231 | MCF-7 | |
| 1 | 26.6 | 25.6 | 19.2 | >40 | 30.8 |
| 2 | 19.9 | 20.4 | 16.2 | 22.6 | 19.4 |
| 3 | >40 | 38.5 | 39.7 | >40 | >40 |
| 4 | >40 | >40 | >40 | >40 | >40 |
| 7 | >40 | >40 | >40 | >40 | >40 |
| 8 | >40 | >40 | >40 | >40 | >40 |
| paclitaxel (nM) | 0.99 | 0.80 | 1896 | 3.05 | 22.75 |
a
A549 (lung carcinoma), KB (epidermoid carcinoma of the nasopharynx), KB-VIN (P-gp-overexpressing MDR subline of KB), MDA-MB-231 (triple-negative breast cancer), MCF-7 (estrogen receptor-positive and HER2-negative breast cancer).
b
Antiproliferative activity as IC50 values for each cell line, the concentration of compound that caused 50% reduction relative to untreated cells determined by the SRB assay.